Effects of a Behavioral Sleep Extension Intervention on Cardiometabolic Risk Factors Among Patients With Elevated BP/Hypertension
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Elevated Blood Pressure
- Sponsor
- University of Utah
- Enrollment
- 120
- Locations
- 1
- Primary Endpoint
- Sleep duration
- Status
- Active, not recruiting
- Last Updated
- last year
Overview
Brief Summary
The goal of this study is to test the efficacy of a behavioral sleep extension intervention on sleep duration, cardio-metabolic disease risk factors, and health behaviors among adults with elevated blood pressure/hypertension and short sleep duration.
Detailed Description
Half of U.S. adults have at least one cardio-metabolic disease (CMD), including hypertension (HTN), heart disease, stroke, or diabetes. Even with advances in screening, education, and medication management, controlling these chronic diseases remains challenging. Despite the well-established negative effects of short sleep duration, surprisingly few studies have tested the benefits of sleep extension and even fewer studies evaluate the science of sleep extension interventions. Therefore, the goal of this study is to test the efficacy of a behavioral sleep extension intervention on sleep duration, CMD risk factors, and health behaviors among adults with elevated BP/HTN and short sleep duration.
Investigators
Kelly Glazer Baron
Professor
University of Utah
Eligibility Criteria
Inclusion Criteria
- •Age 18-65
- •24h ABP readings indicating elevated blood pressure (BP) or hypertension (24h average systolic (SBP) of 115-145 mmHg or diastolic (DBP) of 75-90 mmHg). Patients taking antihypertensive medications will be permitted if stable dose for \>8 weeks
- •Time in bed \<8 hours and habitual sleep duration \<7 hours via actigraphy;
- •Smartphone user
- •Able to read/write in English.
Exclusion Criteria
- •High risk or presence of moderate to severe comorbid sleep disorders (i.e., obstructive sleep apnea AHI 15 or greater, restless legs syndrome, or insomnia) as assessed by the questionnaires and overnight obstructive sleep apnea at the baseline/screening
- •Resistant hypertension, defined as \>4 antihypertensive medications or taking medications and standardized in lab BP \>130 mmHg SBP or 80 mmHg DBP at screening History of cognitive or neurological disorders (e.g. dementia, Parkinson's, Multiple Sclerosis)
- •BMI\>50 kg/m2 or arm circumference greater than extra large cuff
- •Presence of major psychiatric disorders (e.g. schizophrenia, bipolar disorder)
- •alcohol abuse on the Audit-C (score \>4 for men, \>3 for women)
- •drug use on the NIDA-Modified ASSIST (score \>3),90
- •moderate to severe depressive symptoms (PHQ-8 \>10)
- •Unstable or serious medical illness that would interfere with participation (cancer, renal disease on dialysis)
- •Overnight work more than 1x per month
- •Use of hypnotic or stimulant medications
Outcomes
Primary Outcomes
Sleep duration
Time Frame: 8 weeks
Sleep duration will be measured using wrist actigraphy for 7 days
Secondary Outcomes
- 24 hour ambulatory blood pressure(12 months)
- Sleep duration(12 months)